Astrazeneca Ab
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.8Mgeneral payments (2019-2025)
$21Kresearch payments (2019-2025)
441clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Andexxa $38K associated (2023-2025)
- Fasenra $21K associated (2023-2025)
- Tezspire $17K associated (2023-2025)
- Imfinzi $7,940 associated (2023-2025)
- Airsupra $6,588 associated (2023-2025)
- Lokelma $4,258 associated (2023-2025)
- Breztri $4,028 associated (2023-2025)
- Movantik $1,125 associated (2023-2025)
- Truqap $685 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| S Claiborne Johnston | San Francisco, CA | Neurology (Psychiatry & Neurology) | $80,747.44 |
| Satish Shah | Gettysburg, PA | Hematology & Oncology | $80,509.76 |
| Michael Wechsler | Denver, CO | Pulmonary Disease | $73,317.14 |
| Silvio Inzucchi | New Haven, CT | Endocrinology, Diabetes & Metabolism | $61,435.00 |
| Myles Wolf | Chicago, IL | Nephrology (Internal Medicine) | $50,800.00 |
| Glenn Chertow | Stanford, CA | Nephrology (Internal Medicine) | $40,475.00 |
| Meilan Han | Ann Arbor, MI | Pulmonary Disease | $37,517.92 |
| Kevin Murphy | Boys Town, NE | Allergy & Immunology | $29,307.10 |
| William Peacock | Houston, TX | Emergency Medicine | $29,200.00 |
| Jonathan Corren | Los Angeles, CA | Clinical & Laboratory Immunology (Allergy & Immunology) | $28,107.42 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.